Discover Qazaqstan via News and Inspiring Stories
QazMonitor Logo
Facebook Qazmonitor iconInstagram Qazmonitor iconTiktok Qazmonitor iconTwitter Qazmonitor iconTelegram Qazmonitor iconYoutube Qazmonitor icon
  1. Main Page
  2. News
  3. Pfizer Intends to Open Production of Pneumococcal Vaccines in Kazakhstan
  1. News
  2. News
Astana, Kazakhstan • 27 February, 2023 | 09:51
1 min read

Pfizer Intends to Open Production of Pneumococcal Vaccines in Kazakhstan

The healthcare ministry has agreed to localize production of the PREVNAR 20 vaccine

QazMonitor Logo

Healthcare minister Azhar Giniyat met with the regional representatives of the multinational pharmaceutical and biotechnology corporation Pfizer and discussed the opening of vaccine production in the country, QazMonitor reports.

Pfizer Inc. is a multinational American pharmaceutical corporation specializing in the production of drugs and vaccines used in immunology, oncology, cardiology, endocrinology, and neurology. In 2020, the company collaborated on the development of the Pfizer-BioNTech COVID-19 vaccine.

Pfizer’s PREVNAR 20, or Pneumococcal 20-valent Conjugate Vaccine, is used to prevent pneumococcal disease, the most common of which is pneumonia.

According to the healthcare minister, the parties agreed on the implementation of several projects aimed at the introduction of advanced methods of screening and treatment of diseases in Kazakhstan.

“The next milestone of our cooperation will be the production of Pfizer's new generation PREVNAR 20 vaccine in Kazakhstan," said Giniyat.

Only 30% of an article published on The Qazaqstan Monitor website may be used with a mandatory hyperlink provided to indicate the original source. To re-publish the full article, written permission from the editorial is required.